Alivus Life Sciences Peer Comparison

NSE: GLS | BSE: 543322

₹1,360.80

₹12.40 (0.92%)

As on 26-Aug-2026IST

Market cap

₹16,697 Cr

Revenue (TTM)

₹2,590 Cr

P/E Ratio

27.7

P/B Ratio

4.8

Div. Yield

0.4 %

Edit

	Alivus Life Sciences	Emcure Pharmaceuticals	Neuland Lab	Concord Biotech	Sudeep Pharma
Market cap (₹ Cr)	16,697	35,233	30,343	16,184	12,763
Revenue (₹ Cr)	2,590	9,683	2,372	1,108	676
Net Profit (₹ Cr)	603.02	1,018.97	497.77	270.18	183.60
Net Margin (%)	22.63	10.47	20.72	23.29	26.06
RoE (%)	19.61	21.30	28.49	14.45	22.72
Price to Earnings	27.69	34.84	60.96	58.77	69.88
Price-To-Book	4.79	6.72	15.01	7.81	13.81

Income Statement (₹ Cr)

	Alivus Life Sciences	Emcure Pharmaceuticals	Neuland Lab	Concord Biotech	Sudeep Pharma
Operating Revenue	2,551.83	7,896.00	2,022.99	1,054.89	642.26
Total Income	2,612.24	7,968.78	2,053.15	1,107.25	670.84
Total Expenditure	1,754.55	6,427.14	1,448.49	686.95	419.46
EBITDA	797.28	1,468.85	574.50	367.94	222.80
Depreciation	75.36	384.13	91.74	74.46	14.81
EBIT	721.93	1,084.73	482.76	293.48	207.99
Interest	5.37	175.78	23.95	0.82	8.50
Other Income	60.41	72.79	30.17	52.36	28.59
Exceptional Items	-25.66	-10.38	76.40	-3.28	--
Profit before Tax	751.31	971.35	488.98	344.65	228.07
Provision for Tax	186.83	263.88	124.98	85.42	53.79
Profit after Tax	564.48	707.47	364.00	259.23	174.28

	Alivus Life Sciences	Emcure Pharmaceuticals	Neuland Lab	Concord Biotech	Sudeep Pharma
Shareholder's Funds	3,332.13	4,446.19	1,874.47	2,017.06	883.34
Minority Interest	--	195.37	--	-1.92	14.75
Non-Current Liabilities	142.73	811.91	345.47	47.58	74.33
Current Liabilities	682.24	2,668.27	710.20	169.08	201.96
Total Liabilities	4,157.10	8,121.73	2,930.14	2,231.79	1,174.38

	Alivus Life Sciences	Emcure Pharmaceuticals	Neuland Lab	Concord Biotech	Sudeep Pharma
Non-Current Assets	1,333.54	3,565.87	1,447.01	981.68	550.42
Current Assets	2,823.56	4,555.86	1,483.13	1,250.11	623.97
Total Assets	4,157.10	8,121.73	2,930.14	2,231.79	1,174.38
Total Debt*	0.00	730.70	196.61	0.00	148.29
Net Current Assets	2,141.33	1,887.59	772.93	1,081.03	422.00
Contingent Liabilities	4.82	393.94	13.18	3.76	0.10

	Alivus Life Sciences	Emcure Pharmaceuticals	Neuland Lab	Concord Biotech	Sudeep Pharma
Cash From Operating Activities	565.41	851.71	346.68	266.88	69.55
Cash Flow from Investing Activities	-570.15	-94.00	-423.73	-142.72	-330.93
Cash from Financing Activities	-64.34	-813.96	20.98	-112.88	247.29
Net Cash Inflow / Outflow	-69.08	-56.25	-56.08	11.28	-14.09

	Alivus Life Sciences	Emcure Pharmaceuticals	Neuland Lab	Concord Biotech	Sudeep Pharma
ROCE (%)	24.61	22.49	27.50	18.04	28.50
ROE (%)	18.41	19.19	21.43	13.54	25.37
ROA (%)	14.27	8.94	14.25	12.15	18.43
EBIT Margin (%)	33.61	19.52	29.89	39.84	39.14
Net Margin (%)	21.61	8.88	17.73	23.41	25.98
Cash Profit Margin (%)	24.81	13.61	22.53	31.63	28.90

	Alivus Life Sciences	Emcure Pharmaceuticals	Neuland Lab	Concord Biotech	Sudeep Pharma
Revenue Growth (%)	6.91	18.59	36.98	-12.10	27.94
EBIT Growth (%)	19.60	19.81	75.89	-23.76	25.48
Net Profit Growth (%)	16.24	34.10	39.94	-30.25	25.63
EPS Growth (%)	16.05	30.75	39.94	-29.80	7.28
Book Value Growth (%)	18.43	50.94	22.95	11.27	79.97

	Alivus Life Sciences	Emcure Pharmaceuticals	Neuland Lab	Concord Biotech	Sudeep Pharma
Price / Earnings	21.18	29.84	42.34	40.73	38.70
Price / Book Value	3.60	4.58	8.23	5.27	7.57
Dividend Yield (%)	0.51	0.28	0.28	0.74	0.25
EV/EBITDA	13.94	13.55	25.23	25.25	26.75
Market Cap (₹ Cr)	11,956.86	20,327.45	15,412.11	10,627.92	6,690.53

	Alivus Life Sciences	Emcure Pharmaceuticals	Neuland Lab	Concord Biotech	Sudeep Pharma
Debt to Equity	0.00	0.16	0.10	0.00	0.17
Short term debt to equity ratio	--	0.11	--	0.00	0.12
Current Ratio	4.14	1.71	2.09	7.39	3.09
Quick Ratio	3.12	0.98	1.37	5.46	2.02
Interest Coverage	140.86	6.53	21.42	419.57	27.82

	Alivus Life Sciences	Emcure Pharmaceuticals	Neuland Lab	Concord Biotech	Sudeep Pharma
Debtors to sales (%)	42.05	25.36	26.76	43.63	35.43
Asset Turnover	0.65	1.01	0.79	0.49	0.69
Receivable days	144.58	87.83	77.32	169.86	115.16
Inventory Days	96.67	78.64	80.83	97.92	96.15
Payable days	135.45	174.97	125.94	159.68	106.08
Cash Conversion Cycle	105.80	-8.50	32.22	108.11	105.23

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.